Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525113 | 1.00 | ATM (0.62) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL18546896 | 0.89 | ALDH1A1 (0.51) | ATMALDH1A1TDP1ERN1TSHR | |
| SCHEMBL20094434 | 0.86 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL7395208 | 0.86 | ATM (0.59) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL25263843 | 0.85 | ATM (0.54) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL30547505 | 0.85 | ATM (0.54) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL56951 | 0.84 | ATM (0.77) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL20419468 | 0.83 | ATM (0.56) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL23990370 | 0.83 | ATM (0.56) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL7392209 | 0.83 | ATM (0.56) | ATMALDH1A1CYP2A6CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ATM 3086/4885ALDH1A1 164/4885CYP2A6 590/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ATM 3086/4885ALDH1A1 164/4885CYP2A6 590/4885 |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | ATM 4537/4885ALDH1A1 3976/4885CYP2A6 4875/4885 |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | ATM 3525/4885ALDH1A1 4410/4885CYP2A6 2898/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ATM 3086/4885ALDH1A1 164/4885CYP2A6 590/4885 |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, LIPC, PCSK9 | ATM 2557/4885ALDH1A1 1541/4885CYP2A6 447/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | ATM 3659/4885ALDH1A1 287/4885CYP2A6 1602/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | ATM 4537/4885ALDH1A1 3976/4885CYP2A6 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.